Ozempic Goes Generic —But Not in the US
A drug that helped turn Novo Nordisk into Europe’s most valuable company is about to lose its…
Coming Soon: ‘Wegovy HD’
Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may…
An interview with Novo Nordisk’s Irish boss – The Irish Times
Dilek Dogan Gurluk wants to know what Irish summers are like. The new general manager of Novo Nordisk’s…
The Best Healthcare Stocks to Buy With $50 Right Now
It’s not hard to find healthcare stocks, including small-cap biotech companies, trading below $50 per share. However, many…
FDA sends letter to Novo Nordisk over potential GLP-1 side effects
The U.S. Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of…
FDA sends letter to Novo Nordisk over potential GLP-1 side effects
The U.S. Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of…
WHO Foundation and Novo Nordisk Expand Collaboration to Provide Financial Support towards strengthening health systems for Cardio-Renal-Metabolic Diseases
GENEVA, March 11, 2026 /PRNewswire/ — The WHO Foundation today announced an expanded collaboration with Novo Nordisk to support…
Weight-loss wegovy jab may carry greater risk of sudden sight loss, study finds – The Irish Times
Patients taking Wegovy have nearly five times the risk of sudden sight loss compared with those on Ozempic,…
Hims & Hers will sell real Ozempic in deal with Novo Nordisk
Hims & Hers and the Danish pharma giant Novo Nordisk have ended a bitter legal feud that will…
FDA warns Novo Nordisk over unreported potential Ozempic side effects
Novo Nordisk, the pharmaceutical company behind Ozempic, has received a warning letter from the U.S. Food and Drug…
The era of $199 copycat weight loss drugs is ending — and it could cost patients
After two splashy Super Bowl commercials focused on making weight loss medication more accessible, Hims & Hers will…
Weight-loss drug pioneer announces €432m investment to build pill plant in Athlone – The Irish Times
Weight-loss drug pioneer Novo Nordisk will invest €432 million in upgrading its Athlone plant to produce the tablet…